Socio-medical studies of individuals self-treating with helminths provide insight into clinical trial design for assessing helminth therapy

Aarushi Venkatakrishnan\(^{a}\), Joshua T. Sarafian\(^{a}\), Katerina Jirků-Pomajbíková\(^{b, c}\), William Parker\(^{a,d}*,\)

\(^{a}\) Department of Surgery, Duke University School of Medicine, Durham, NC, USA
\(^{b}\) Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 370 05 České Budejovice, Czech Republic
\(^{c}\) Faculty of Science, University of South Bohemia, 370 05 České Budejovice, Czech Republic
\(^{d}\) Duke Global Health Institute, Duke University and Duke University Medical Center, Durham, NC 27710, USA

1. Introduction

Intestinal worms, called helminths, have been almost completely eliminated in Western countries by widespread use of toilets, refrigerators, food storage technologies, and various food preservation techniques [1–3]. Although helminths in general cause a significant burden of disease, many helminths are benign [2] and, as a result, remain relatively unknown. Unfortunately, the loss of all helminths, both pathogenic and benign, from the ecosystem of the human body profoundly increases the propensity for chronic inflammation–associated disease in Western Society. The nature of immune system dysfunction caused by the loss of helminths is readily deduced based on the emergence of disease with the concomitant loss of helminths [4] and the effects re-introducing helminths into the population. For example, in the 1970s, seminal observations made by investigators in the UK demonstrated that exposure to helminths eliminated allergic disease [5,6]. Other studies conducted at the same time [7–10], confirmed by additional work decades later [11,12], demonstrated that exposure to helminths prevents autoimmune diseases. More recent evidence has connected the loss of helminths with some inflammation-associated neuropsychiatric disorders, including a variety of anxiety disorders and major depressive disorder [13,14]. Further, numerous studies have elucidated a variety of immunological mechanisms underlying helminth therapy, including production of a wide range of helminth-derived immunoregulatory molecules, induction of regulatory networks, and activation of otherwise dormant immune components [15–20]. In light of this information, it is perhaps unsurprising that thousands of individuals today use helminths to treat their chronic inflammatory conditions [13,21,22].

Systematic data gathering from people “self-treating” with helminths was first suggested by Flowers and Hopkins in 2013 [23] as an effective method for obtaining information regarding the effects of therapeutic helminths on patients with chronic immune related disease. Unfortunately, clinical trials approved by regulatory agencies probing the effectiveness of helminth therapy have been limited, in part by intellectual property rights [24] and regulatory issues [25]. Such issues are

---

\(^{*}\) Corresponding author at: WPLab Inc., 1023 Wells St, USA.
E-mail address: William.Parker@WilliamParkerLab.org (W. Parker).

https://doi.org/10.1016/j.parint.2021.102488
Received 9 September 2021; Received in revised form 25 October 2021; Accepted 27 October 2021
Available online 1 November 2021
1383-5769/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
not easily overcome. For example, it may prove difficult to patent a naturally occurring organism for helminth therapy, and, as pointed out by a team of pharmaceutical industry specialists from Boehringer Ingelheim, one of the world’s largest pharmaceutical companies, corporations cannot “shoulder the enormous costs involved” in clinical trials without patent protection for their investments [24]. Such investment without patent protection would potentially defraud investors and put the company at risk, both financially and legally. Further, current regulations are designed for testing of pharmaceutical compounds that are extremely well defined in terms of their physical/chemical properties. A given species of helminth, on the other hand, may be cultivated in dozens of ways and may have genetic variation. Characterization of the clinical impact of each individual variation would be a cost-prohibitive endeavor. Unfortunately, as will be discussed in some detail in this manuscript, factors associated with formulation of therapeutic helminths may have profoundly impeded at least some clinical trials performed to date. Thus, at the present time, systematic data gathering from individuals self-treating may be the most practical and effective means of evaluating the effects of helminth therapy. Importantly, this view does not ignore the vital importance of clinical trials, which ultimately must be conducted before helminth therapy can be utilized in mainstream medicine.

Previous studies collecting information from individuals self-treating with helminths [13,21,22] have encompassed four helminths, a wide range of disease, and more than 1000 individual cases. Data collection methods include surveys, interviews with helminth providers, and interviews with physicians who have experience observing patients who are self-treating. Information concerning the use of four helminths has been collected: the porcine whipworm (TSO), the human whipworm (TTO), the human hookworm (NA), and the rat tapeworm (HDC). This assortment of helminths was “selected” for use by self-treaters more by happenstance than by design [26], but provides a range of alternatives for self-treaters in terms of both financial costs and benefit/risk ratios [26].

Prior studies evaluating the outcomes of individuals self-treating with helminths [13,21,22] have utilized a series of methods, including surveys for self-treating individuals, surveys for physicians who monitor self-treating individuals, and interviews with producers and suppliers of helminths. In some cases, survival bias and response bias have been either eliminated or quantified, and several lines of evidence, outlined in the Discussion, indicate that placebo and nocebo effects contribute minimally to reported outcomes. Conclusions are considered strongest when supported by multiple approaches, and especially in cases where results of self-treatment match published clinical observations. For example, prospective studies evaluating the effect of accidental helminth colonization on relapsing remitting multiple sclerosis [11,27] have corroborated studies in individuals self-treating their multiple sclerosis with helminths [13,21]. In addition, clinical observations [5] have corroborated positive results obtained by individuals self-treating their seasonal allergies with helminths [13,21]. Other conclusions based on evaluation of individuals self-treating with helminths have been validated in studies using laboratory animal models. For example, studies in animal models [9,10] have corroborated positive results obtained by individuals self-treating with helminths to alleviate autoimmune conditions such as lupus and some cases of arthritis [13,21]. Studies in animal models [14] have also corroborated positive results obtained by individuals self-treating with helminths to alleviate neuropsychiatric disorders [13,22].

Although self-treatment with helminths is apparently beneficial to many individuals with some disorders, studies of individuals self-treating with helminths have revealed limitations to the therapy. For example, self-treatment with helminths may effectively treat relapsing remitting multiple sclerosis and alopecia areata [13,21,22], but may not be as effective at treating more advanced stages of these conditions, progressive multiple sclerosis and alopecia totalis. Further, helminth therapy may effectively treat seasonal allergies, but may have little beneficial effect for individuals suffering from chronic exposure to household mold. Thus, studies of individuals self-treating with helminths reveals benefits as well as limitations to the therapy.

In this study, we provide a series of new findings that add to our previous socio-medical studies. Importantly, new information highlights the importance of two factors that may not be adequately considered in some recent clinical trials: (a) individualized dosage requirements and (b) helminth preparation and storage conditions. These findings suggest that the current “gold standard” trials [28], despite their double-blind, placebo-controlled design, are providing lackluster or even false negative results due to a lack of consideration of the biology of helminths and their interactions with their hosts. That being said, helminth therapy is not expected to resolve all chronic inflammatory conditions, an expectation supported by studies of individuals self-treating with helminths. Thus, as we begin to understand and implement effective design of clinical trials for helminth therapy, limitations to the therapy will doubtless emerge as benefits to the therapy are identified.

2. Methods

2.1. General methods

Studies were approved by the Duke Institutional Review Board. All research was performed in accordance with relevant guidelines/regulations, and informed consent was obtained as dictated in the approved protocol. At no time was any protected health information gathered, and no personally identifying information was collected, ensuring anonymity of the participants. This study, as with our previous studies [13,21], utilized multiple approaches to probe the outcomes of self-treatment with helminths. As previously described [21], the multiple methodologies facilitated acquisition of more diverse information than would have been obtainable with a single method alone, and allowed triangulation between methods to strengthen conclusions regarding some aspects of the practice of self-treatment with helminths. In this study, three approaches were used to evaluate current practice and outcomes in self-treatment with helminths. First, individuals prominent in the self-treatment community were interviewed. These included individuals producing, selling, and/or distributing helminths (“providers”) for self-treatment with helminth therapy, and individuals compiling and organizing data regarding outcomes of self-treatment in a public format. As a second approach, publicly available information regarding self-treatment with helminths was compiled and evaluated. Third, physicians (all board-certified MDs) who see patients that self-treat with helminths were interviewed.

2.2. Assessment of dosing recommendations by evaluation of publicly available information

To provide information regarding the range of hookworm doses used for self-treatment, publicly available, self-reported personal experiences with dose adjusting using the human hookworm were examined. This approach does not control for survivor bias, and is thus not useful as an absolute measure of effectiveness of helminth therapy. Further, the data obtained cannot be taken as evidence that helminth therapy actually “works”, or has a good benefit to cost ratio when applied by knowledgeable practitioners. The view that helminth therapy works is based on other studies, as described in the Introduction. Finally, additional caveats to this approach need to be kept in mind, some of which are described in the Results section. Nevertheless, the approach was useful in probing the range in effective dose of hookworm as reported by self-treaters. Helminthic Therapy Wiki (“Helminth Wiki”), a popular crowdsourced site that consolidates information about helminth therapy, was used as an initial source of information. Most of the reports on Helminth Wiki came from a Yahoo group, “Helminthic Therapy Forum,” and the “Helminthic Therapy Support” Facebook Group. While the Yahoo group was the longest active forum for helminth users, in December 2019
Yahoo removed all user content from its groups, leaving the information to be solely held on Helminthic Therapy Wiki. In the Facebook group, posts between January 2012 and December 2019 in were reviewed and users’ personal experiences with dose adjustments were recorded. Two illnesses with the highest number of selected cases on the Wiki site were evaluated: Allergy and Crohn’s colitis. Independent searches were conducted using the keywords “Allergy” or “Crohn’s” and modifying the parameters to focus on a specific year in the date range. Cases were omitted if (a) the physical condition was not either allergies or Crohn’s colitis, (b) the dose of helminths used was not specified, or (c) any helminth other than the hookworm was used, even if it was used in combination with the hookworm. Since this study was focused on the dosage used for effective therapy, cases that did not report a positive effect of helminth therapy were also excluded. In all remaining cases, the doses of helminth used were recorded and analyzed.

3. Results

3.1. General

The four helminths currently used for self-treatment are the same ones that have been used for about 7 years. The most recent addition for self-treaters was the rat tapeworm (HDC) in 2013. However, the popularity of various helminths continues to shift, with the human whipworm (TTO) becoming less popular due to a relatively high cost/benefit ratio compared to other helminths, and a lack of advantages over other helminths (Table 1). The observation that HDCs appear to be an effective therapeutic substitute for TTO was made by one of the most experienced helminth suppliers and has not been previously reported. Given that HDCs have a lower risk profile than TTO, it is anticipated that HDCs will continue to increase in popularity, while TTO decreases in popularity. However, the choice between different helminths for most individuals continues to be a balance between higher-cost helminths (TSO and HDC) that do not effectively colonize humans, and lower cost helminths that effectively colonize humans (TTO and NA). Further, it is expected that individuals who have had success with TTO in the past will continue to use the organism for therapeutic purposes.

3.2. Growth of self-treatment

No therapeutic helminth has yet been approved for use by the FDA. Further, at least two suppliers have tried to obtain approval through regulatory agencies for helminths as a novel food. These efforts have thus far not met with success. Nevertheless, self-treatment with helminths has continued to grow as judged by the number of companies currently providing helminths. The total number of helminth suppliers more than doubled between 2014 and 2020 (Fig. 1). A list of current suppliers can be found in Table 2. The table excludes commercial suppliers who inform the study team that they did not wish to be publicly identified. In addition, “helmTX” is not included. Although they describe their helminth as “FDA approval pending”, they do not currently provide helminths for self-treaters. Suppliers include some established brick and mortar facilities (e.g., Tanawisa, Biome Restoration, Worm Therapy, The Llamas Clinic) as well as others who can only be found on the internet or via Email (e.g., Autoimmune Therapies, Au Naturel, Your-Symbionts). As shown in Fig. 1, the number of suppliers providing HDCs and NA has expanded considerably. TSO, on the other hand, continues to be produced only by Tanawisa.

3.3. Publicly organized data: helminth therapy Wiki

Information regarding helminth therapy from social media groups such as Facebook and Yahoo has been available to the public for a number of years [21]. Perhaps the biggest development in terms of social organization for self-treaters is the extensive development of a website designated exclusively for helminth therapy results. This

---

**Table 1**

| Helminth | Pros | Cons |
|----------|------|------|
| NA       | • May be more potent that other helminths under some conditions, especially for lung-associated conditions. | • Beneficial effects can take months to mature: titrating dose is time-prohibitive in many cases. |
|          | • Least expensive of all helminths: Easy to self-cultivate. | • Side effects from over-exposure can be severe. |
|          | • Abundant data from self-treaters available. | • Isolated from human feces. |
| TSO      | • Best tested for safety in clinical trials. | • Purification (cleaning) for FDA-approved use may adversely affect the organisms’ efficacy. |
|          | • Almost always non-colonizing. | • Clinical data available, but probably do not reflect optimized therapeutic approach. |
|          | • Minimal or no side effects when dose is carefully titrated. | • Utilizes blood for survival. |
| HDC      | • Usually non-colonizing. | • Currently more expensive than other helminths. Impossible to cultivate without extensive resources. |
|          | • Minimal or no side effects when dose is carefully titrated. | • Can take longer than HDCs for beneficial effects to mature. |
|          | • Faster acting than other helminths. (Beneficial effects mature faster.) | • Clinical data available, but probably do not reflect optimized therapeutic approach. |
|          | • Isolated from an edible host (grain beetle) | • Isolated from pig feces. |
|          | • Abundant data from self-treaters available. | • Storage conditions, especially the pH, are potentially important but have not been agreed upon by the scientific community. |
|          | • Does not encroach on host tissue: remains in the lumen of the gut. | • Limited data from self-treating community available. |
| TTO      | • Well studied in isolated cases. | • More expensive than NA. |
|          | • Can make disease worse in some cases. | • Time consuming to cultivate. |
|          | • Time consuming and difficult to cultivate. | • Requires specialized facilities. |
|          | • Limited utility: Not suggested for most conditions. Works well for ulcerative colitis, but HDCs is also effective in those cases. | • Rapid spoiling on storage, increasing cost of shipping. |

---

![Fig. 1](image-url)  
**Fig. 1.** Emergence of companies selling various helminths. Only companies currently supplying helminths are shown on the graph; companies no longer in business are excluded. In addition, companies which do not wish to be recognized publicly are not shown on the graph.
Table 2
Current helminth suppliers, helminths supplied, and the date when access began.

| Helminth supplier name                      | Helminth(s) provided | Year product released |
|--------------------------------------------|----------------------|----------------------|
| Tanawisa                                   | TSO                  | 2004                 |
| Autoimmune Therapies                       | NA                   | 2007                 |
| Worm Therapy                               | NA                   | 2008                 |
| Biome Restoration Ltd                      | HDC                  | 2013                 |
| Symmbio                                    | NA                   | 2016                 |
| The Llamas Clinic                          | NA                   | 2018                 |
| YourSymbiotics                             | NA                   | 2018                 |
| Helminth Therapy Aust & NZ (formerly Brisbane Naturapaths) | HDC                  | 2019                 |
| Au NAturel                                 | NA                   | 2019                 |

Most of the providers listed were at one time working with other suppliers or are still affiliated with other suppliers.

Table 3
Dose range for helminths commonly used for therapeutic purposes.

| Set point (number of organisms/time)       | Low set point | Mid-range set point | High set point |
|--------------------------------------------|---------------|---------------------|----------------|
| Hookworm (NA)                              | 2-5/3 months  | 15-20/3 months     | 50/3 months    |
| Porcine whipworm (TSO)                     | 200/0 weeks   | 2500/2 weeks        | 7500/10 days   |
| Rat Tapeworm (HDC)                         | 2-5/6 weeks   | 20-40/4 weeks       | 200/1 week     |

Insufficient information regarding the use of human whipworms (TSO) exists to establish set point ranges.
helminths typically have chronic conditions associated with immune dysfunction, it might be hypothesized that the rate of colonization of children with uncompromised immune systems by these organisms is vanishingly small.

NA has frequently been administered on the forearm. However, treatment with NA by most self-treaters now utilizes application to the feet rather than the forearm. The view that this approach causes substantially less irritation at the site of entry of the organisms was corroborated by two physicians and one supplier. NA has a strong affinity for human skin [34], and is transferred from host-to-host via exposure of the skin to soil containing the organisms [35]. With this in mind, it seems likely that the natural point of entry into human skin would be areas on the body that are calloused due to regular contact with soil. The same supplier who noted that NA washed free of bacteria is less effective than unwashed NA (see above) also noted that NA washed free of bacteria caused less irritation at the site of entry. While this observation could be attributed to damage or attenuation of the NA during the washing procedure, it might also suggest that the bacteria carried with the NA are capable of causing irritation as the helminth moves through the skin. If that is correct, then it seems likely that, when NA enters the skin through a calloused area of the body, some of the microbial components are deposited in the callous, resulting in decreased irritation when the NA reaches a vascularized area.

Self-exposure to NA was reported by one helminth supplier to alleviate most (~70%) of the symptoms of narcolepsy without cataplexy, consistent with the previously held view [36] that helminth therapy can treat a wide range of neurological disorders associated with chronic inflammation, including anxiety disorders and major depressive disorder [13].

Mast cell disorders and fibromyalgia have previously been reported to be contra-indications for helminth therapy due to adverse reactions to the symbionts in patients with these conditions [21]. This conclusion has been corroborated by an additional supplier. In addition, a supplier with extensive experience in the application of helminth therapy and with

Fig. 2. Variation in dosage of the human hookworm (NA) from self-reported, successful treatment of allergies and Crohn’s colitis. The self-reported dosing strategy taken by individuals with allergies (n = 25) and Crohn’s (n = 16) is shown in panels A and B, respectively. Open circles represent instances where an individual determined that their dose was too high and started to worsen their condition. Panel C shows a comparison between the starting dose of NA taken between self-treaters with allergies (n = 32, mean = 20.22, std. deviation = 13.88, std. error = 2.454) and those with Crohn’s (n = 23, mean = 20.61, std. deviation = 13.62, std. error = 2.841) p = 0.8696. Panel D compares the cumulative dose, normalized per year, for self-treaters with allergies (n = 25, mean = 90.25, std. deviation = 86.86, std. error = 17.57) and those with Crohn’s (n = 16, mean = 102.6, std. deviation = 62.04, std. error = 15.51) p = 0.1857.
ties to a clinic treating patients with helminths reports that fistulating Crohn’s disease is also a contra-indication for helminth therapy.

3.6. A persistent question: does preparation and storage of TSO affect its efficacy?

TSO is the organism that has been most often used by individuals self-treating with helminths [21]. Based on socio-medical studies [13,21], we have concluded that, consistent with earlier successful trials [37,38], TSO is indeed effective. Roughly a third of patients with a wide range of chronic inflammatory conditions experience “profound” or “dramatic” improvements of chronic conditions, with less than 1% of individuals experiences adverse reactions worse than temporary gastrointestinal upset. However, the therapeutic effect of the organism has not born out well in clinical trials [39,40]. An explanation for these conflicting observations is adamantly supported by the supplier of TSO. Prior to the report of the first failure of a clinical trial with TSO, our socio-medical study received reports from the supplier that clinical trials utilized organisms that were poorly prepared, thereby decreasing their efficacy [21]. The central question regarding preparation of the organism deals with the acidity of the solution in which the organisms are suspended: pH of storage, how fast the pH is changed prior to administration to patients, and how long it sits at a particular pH prior to administration.

As mentioned above and discussed previously [21], controversy regarding the preparation of TSO centers around the pH of the preparation. During the initial isolation of TSO in preparation for clinical use, the pH is lowered dramatically (pH approximately 1.0) to inactivate pathogens that may be present in the porcine feces from which TSO is harvested. Then the pH is raised at least to pH 2.5 prior to storage. This process differs substantially from the pH encountered by the organism during its natural life cycle, in which a low pH is only temporarily encountered in the distal porcine stomach immediately following ingestion (Fig. 4). As shown in Fig. 4, the pH of therapeutic preparations of TSO can vary dramatically and depends on the preparation. Further, the method of raising the pH following initial preparation can vary, and the length of time in storage after raising the pH can vary. The manufacturer of TSO for self-treatment contends that only by raising the pH

Fig. 3. Relationship between the initial dose of hookworm and the last reported dose (A), and between the initial dose and the cumulative dose per year (B). For this analysis, self-reported data from individuals treating allergies and Crohn’s colitis were combined and analyzed together. Correlations were statistically significant but weak for both comparisons: (A, n = 41, r² = 0.3159, p = 0.0001) (B, n = 41, r² = 0.4239, p ≤0.0001). The average time until last dose for allergies was 1.48 years (17.72 months), and was 1.31 years (15.69 months) for Crohn’s colitis.

Fig. 4. Fluctuations in pH during (A) the natural life cycle of TSO and during (B, C) two methods of preparation. After passing through the pig gut at pH 6.1–6.6, TSO is deposited in soil [56,57]. Geohelminths can survive in both slightly acidic and alkaline soils, with studies reporting presence of helminths between pH 5.21–9.9 [58–60]. Ingestion in the pig occurs between approximately pH 6.7 [61], and acidity increases as the TSO reaches the pig’s anterior stomach at pH 4.4 and then the posterior stomach at pH 2.6 [57,62,63]. As the TSO reach the pig’s small bowel between pH 6.1–6.7, the helminth hatches. For clinical use in humans, TSO is purified from pig feces using strongly acidic conditions (pH 1) to inactivate viruses (B, C). After purification, the TSO is either stored at a low pH of 2.5 (B), or a relatively higher pH of 5 (C). The supplier of TSO for self-treatment asserts that only method (B) produces effective organisms, whereas the methods used in clinical trials have involved method (C) and may vary from study-to-study. TSO is ingested by humans at approximately pH 6.7 [64,65], and reaches the stomach at pH 1.7 [66,67]. Lastly, the TSO hatches in the small bowel at pH 6 [68]. Arrows preceding breaks in the graph represent the TSO remaining in the soil or in storage for an unspecified time.
moderately (i.e., up to pH 2.5) and slowly can effective TSO be maintained. Based on their customer feedback, they contend that raising the pH to as high as 5.5 prior to storage can render the TSO ineffective over time. Despite the fact that TSO has been used in clinical trials, the effect of pH on the viability of the organism and its ability to hatch has not been investigated. Some work has been done with the mouse whipworm [41], but results from studies using the mouse whipworm may not apply to the porcine whipworm [42].

Given that helminth suppliers often receive regular feedback on their preparations from their customers, their measure of efficacy can be both extremely rapid and clinically relevant. Individuals running clinical trials, on the other hand, must rely on surrogate markers, such as the hatching of the organisms in an animal model. Unfortunately, at least for preparations from their customers, their measure of efficacy can be both extremely rapid and clinically relevant. Several factors, including advanced age of the organisms and feeding extremely rich diets to their hosts, apparently harm the therapeutic benefit of the organisms [22] without impeding the ability of the organisms to mature in their native hosts. It is indeed difficult to imagine how such sensitivity to the conditions of preparation could be elucidated in clinical trials. The argument has been made that, because the organisms produce some adverse side effects in clinical trials, they must be viable. While this argument certainly has merit, the nature of the side effects is of interest. As an example, Fig. 5 shows intestinal distress reported in one trial [43]. In that trial, in which TSO proved to be ineffective at the dose used, a significant amount of GI distress in some patients following the second dose of the organism was observed, although the GI distress did not persist despite continued treatment. It is unclear whether this temporary increase in side effects demonstrates that the organisms used for the duration of the trial were active, and it is also unclear whether this side effect correlates with the potential for clinical effectiveness.

4. Discussion

At the present time, several clinical trials, reviewed recently [28], have been published using TSO [39], while others have been published using NA [29,44]. Despite (a) numerous positive results in animal models, (b) positive results reported for individuals self-treating with helminths, and, in some cases, (c) positive reports from clinical examination following accidental exposure to helminths [5,11,27], results in clinical trials have been disappointing [40].

Reports from individuals self-treating with helminths, from physicians treating those patients, and from individuals producing therapeutic helminths provides a potential explanation for the lack of positive results in clinical trials: investigators have not taken into account the greater than 10-fold dose range, depending on the individual, that is apparently required to achieve a satisfactory effect. This issue applies to all potentially therapeutic helminths studied to date (Table 3), and presents challenges to clinical trials that would incur considerable time and expense with the implementation of any lengthy dose-finding scheme. For example, one trial with NA used one exposure to 10 organisms over a 16-week period [29], whereas another study used two exposures, one of 10 organisms and another of 5 organisms, over a 20-week period [45]. This level of exposure falls considerably below levels used by many individuals self-treating with helminths (Fig. 2, Table 3), suggesting that it may not be adequate for many individuals. At the same time, higher levels of exposure probably should not be attempted study wide, as such levels would likely cause adverse reactions in many individuals.

Unfortunately and perhaps unavoidably, investigators have apparently been largely unaware that the effectiveness of therapeutic helminths can depend on the production method and storage conditions. This issue is a factor for HDCs and probably for TSO and NA as well. Based on this assessment, we conclude that the conduct of clinical trials needs to be altered significantly, taking into account the biology of helminths as well as the variable immunology of their hosts. If the current trends continue, it seems possible that the therapeutic potential of helminths will be overlooked in favor of pharmacological therapies that are more expensive and potentially less effective. Of considerable concern in this regard is the view that exposure to benign helminths is probably a reasonable preventative measure, whereas treatment with helminth derived products is expected to be utilized only after disease has occurred.

A variety of factors indicate that results reported to us through socio-medical studies are representative of the actual effects of helminth therapy, not artifacts due to placebo effects, normalization to the mean, survivor bias, conflicts with commercial interests, or other issues unrelated to the actual benefits and risks of the therapy. These factors are as follows:

- Survivor bias has been eliminated using some data collection methods (e.g., interviews with physicians and a survey collection method supported by a helminth supplier).
- Reviews, both positive and negative, made by individuals (typically experienced physicians or suppliers) with multiple observations are consistent and corroborating (independent of the commercial interest of the source).
- Reported beneficial effects of therapy are long lasting if the therapy is maintained, inconsistent with the placebo effect.
- Therapy is reported to effectively treat chronic conditions present for decades and despite multiple failures with pharmaceutical approaches, inconsistent with normalization to the mean.
- Therapy has been used to treat degenerative conditions that are irreversible, such as multiple sclerosis, inconsistent with normalization to the mean.
- Beneficial effects of therapy often surprise the users, inconsistent with the placebo effect.
- Therapy has been reported to be effective in small children, who are not prone to influence by expectations or preconditioning.
- Self-treaters indicate that they can tell when their beneficial helminths lose effect and acquisition of more organisms is required.
Ethical approval and consent to participate

Typically needed within a cohort of individuals.

The adverse side effects associated with uncontrolled colonization with helminths and, perhaps to a lesser extent, clinical trials with helminth therapy have led some research groups to pursue helminth derived products (HDPs) rather than helminths themselves as a treatment for inflammatory diseases [46,47]. In January 2020, Capron et al. published the first clinical trial to evaluate the safety of the recombinant helminth protein, P28GST from Schistosoma haematobium, in patients with mild or inactive Crohn’s disease [48]. P28GST was first developed as a vaccine against schistosomiasis, however, researchers have found that the protein has a positive effect in humans and other animal models against inflammation [49–51]. Through their pilot study, they found that the patients experienced a positive response and they assert that using HDPs are a more promising approach as they can replicate the benefits of helminthic therapy without the detriments. The view is that, because the immunomodulatory effectiveness of helminths can be attributed to their surface or excretory/secretory products, therapies can be designed using only these key products [52]. Thus, some researchers, while recognizing the potential benefits of helminthic therapy, have turned away from the use of live helminths and instead pursued HDPs [52–54]. At the present time, however, for theoretical reasons, we do not agree that this approach is warranted: Specifically, we predict that the complexity of the immunoregulation derived from the helminth/host relationship will be impossible to replicate in the foreseeable future using individual components derived from helminths. Here we describe evidence that the efficacy of helminth therapy can be improved and the adverse effects of the therapy can be reduced using personalized dose adjustments over time. Further, we continue to argue that controlled, moderate exposure to domesticated, benign helminths is a practical and cost-effective solution to undermining increases in a variety of hyper-immune related diseases in Western culture [1].

5. Conclusions

Helminth therapy addresses a fundamental cause of chronic inflammatory disease in Western society. In particular, helminth therapy reverses the loss of helminths in Western society that has left the immune system overreactive and prone to allergic, autoimmune, and neuropsychiatric disorders [17,55]. At the present time, we would argue that the primary “lab” for helminth therapy seems to be within the community of self-treaters. This “biohacking” phenomena of science outside of the established main stream is not unique to helminth therapy. However, given that helminth therapy addresses a fundamental cause of disease in Western society, this particular biohacking endeavor may in fact be critical for public health. Unfortunately, for a variety of economic, regulatory, and practical issues surrounding the conduct of clinical trials, main stream trials have thus far been unable to accommodate the nuances of helminth therapy. Foremost among the issues that clinical trials must address before they can effectively test the potential for helminth therapy are (a) details in formulation of the helminth product that affect efficacy, and (b) the very wide range of doses typically needed within a cohort of individuals.

Ethical approval and consent to participate

Studies were approved by the Duke Institutional Review Board. Protocol number Pro00045035 and amendments.

Consent for publication

Not applicable.

Availability of supporting data

Not applicable.

Competing interests

The authors report no conflict of interest and no financial interests in helminth therapy. Authors AV and JTS are affiliated with Duke University Medical Center, which has a vested interest in technology involving the therapeutic use of Hymenolepis diminuta.

Funding

This work was supported in part by the Immunity’s Forge Foundation.

Authors’ contributions

Coauthors AV, JTS and WP collected and analyzed data. WP and KJP designed the study and, with JTS and AV, drafted the manuscript.

Acknowledgements

The authors would like to thank the physicians, suppliers, and others knowledgeable regarding the self-treatment with helminths for altruistically providing the information compiled in this manuscript. The authors also wish to thank John and Susan Poulton for their encouragement and support of this work.

References

[1] W. Parker, S.E. Perkins, M. Harker, M.P. Muehlenbein, A prescription for clinical immunology: the pills are available and ready for testing, Curr. Med. Res. Opin. 28 (2012) 1193–1202, https://doi.org/10.1185/03007995.2012.695731.

[2] W. Parker, J. Ollerton, Evolutionary biology and anthropology suggest biome reconstitution as a necessary approach toward dealing with immune disorders, Evol. Med. Public Health 2013 (2013) 89–103, https://doi.org/10.1093/emph/eot008.

[3] C. Villeneuve, H.H. Kuo, H. Eckermann, A. Palkar, L.G. Anderson, E.A. McKenney, et al., Evolution of the hygiene hypothesis into biota alteration theory: what are the paradigms and where are the clinical applications? Microbes Infect. 20 (3) (2018) 147–155. Epub 2017/11/15, https://doi.org/10.1016/j.micinf.2017.11.001, PubMed PMID: 29133248.

[4] S.W. Bicker, A. DelMaio, Western diseases: current concepts and implications for pediatric surgery research and practice, Pediatr. Surg. Int. 24 (3) (2008) 251–255.

[5] P.J. Preston, The biology of the atopic response, J. R. Nav. Med. Serv. 56 (3) (1970) 229–235. Epub 1970/01/01. PubMed PMID: 5408517.

[6] J.A. Turton, IgE, parasites, and allergy, Lancet. 2 (1968) 1961, https://doi.org/10.1016/s0140-6736(68)90595-3. PubMed PMID: 4174413.

[7] B.M. Greenwood, Autoimmune disease and parasitic infections in Nigerians, Lancet 2 (7564) (1968) 380–382. Epub 1968/08/17, https://doi.org/10.1016/s0140-6736(68)90595-3. PubMed PMID: 4174413.

[8] B.M. Greenwood, E.M. Herrick, A. Voller, Can parasitic infection suppress autoimmune disease? Proc R Soc Med. 63 (1) (1970) 19–20. Epub 1970/01/01. PubMed PMID: 4190594; PubMed Central PMCID: PMCPMC1809490.

[9] B.M. Greenwood, E.M. Herrick, A. Voller, Suppression of autoimmune disease in NZB and (NZB x NZW) F1 hybrid mice by infection with malaria, Nature 226 (5242) (1970) 266–267. Epub 1970/04/18, https://doi.org/10.1038/226266a0. PubMed PMID: 5437516.

[10] B.M. Greenwood, A. Voller, E.M. Herrick, Suppression of adjuvant arthritis by infection with a strain of the rodent malaria parasite Plasmodium berghei, Ann. Rheum. Dis. 29 (3) (1970) 321–323. Epub 1970/05/01. https://doi.org/10.1136/ ard.29.3.321. PubMed PMID: 5432597; PubMed Central PMCID: PMCPMC1031268.

[11] J. Correale, M. Farez, G. Razzitte, Helminth infections associated with multiple sclerosis induce regulatory B cells, Ann. Neurol. 64 (2) (2008) 187–199. PubMed PMID: 18655096.

[12] J. Correale, M. Farez, Association between parasite infection and immune responses in multiple sclerosis, Ann. Neurol. 61 (2) (2007) 97–108. PubMed PMID: PREV200700232269.

[13] J. Liu, R.A. Morey, J.K. Wilson, W. Parker, Practices and outcomes of self-treatment with helminths based on physicians’ observations, J. Helminthol. (FirstView) (2016) 1–11.

[14] L.L. Williamson, E.A. McKenney, Z.E. Holzknecht, C. Belliveau, J.F. Rawls, S. Poulton, et al., Got worms? Perinatal exposure to helminths prevents persistent immune sensitization and cognitive dysfunction induced by early-life infection,
H. Helmby, Human helminths and the modulation of the immune system: friend or foe? Parasitol. Int. 58 (2) (2009) 121–127.

P. Zaccone, Z. Hechtman, J.M. Phillips, D.W. Dunne, A. Cooke, Parasitic worms and inflammatory diseases, Immunol. Rev. 206 (2005) 151–155. Epub 2006/02/23. doi:10.1002/imnr.20066. PubMed PMID: 16440496.

D.A. Jones, The role of helminths in host immunity and health, Trends Parasitol. 29 (2) (2013) 61–68. Epub 2013/01/31. doi:10.1016/j.pt.2012.11.001. PubMed PMID: 23385256.

A. Viswanath, S.N.S. Yarrarapu, M. Williams, In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PubMed PMID: 31024392; PubMed Central PMCID: PMCPMC7995911.

A. Venkatakrishnan et al., Harnessing the helminth secretome for therapeutic immunomodulators, Biomed. Res. Int. 2014 (2014) 964350. doi:10.1155/2014/964350. PubMed PMID: 25460487.

A. Looss, Zur Lebensgeschichte des Trichuris muris. Parasit. 167 (1) (2009) 1–11. Epub 2009/07/22. doi:10.1007/s00436-009-1208-z. PubMed PMID: 19695287. PubMed Central PMCID: PMCP1618732.

V. Heng, P. Ta, A. Royston, J. Sotillo, R. Toledo, J. Mulvenna, A. Loukas, Exploiting helminth Interactomes through big data, Trends Parasitol. 33 (11) (2017) 875–887. Epub 2017/09/11. doi:10.1016/j.pt.2017.07.010. PubMed PMID: 28844863.

G. Riveau, D. Deplanque, F. Remou, A.M. Schacht, H. Vlodounogov, M. Capron, et al., Helminth and immunomodulatory rBST antigen in a randomized, double-blind, placebo-controlled trial, PLoS One 6 (3) (2011), e17366. doi:10.1371/journal.pone.0017366. PubMed PMID: 21408161; PubMed Central PMCID: PMCP3050888.

J. Scholmerich, K. Fellermann, F.W. Seibold, G. Rogler, J. Langhorst, S. Howaldt, et al., A randomized, double-blind, placebo-controlled trial of Trichuris suis ova in active Crohn’s disease, J. Crohns Colitis 14 (11) (2020) 390–399. https://doi.org/10.1093/ecco-jcc/jju184. PubMed PMID: 27707789.

R.W. Summers, D.E. Elliott, J.F. Urban Jr., R. Thompson, J.V. Weinstock, Trichuris suis therapy in Crohn’s disease, Gut 54 (1) (2005) 85–90. Epub 2004/12/23. doi:10.1136/gut.54.1.85. PubMed PMID: 15591509; PubMed Central PMCID: PMCP1773482.

M. Capron, L. Beghin, C. Leclercq, J. Labrecque, A. Dendooven, A. Standaert, et al., Safety of rBST2G, a preparation obtained from a Schistosoma hematobium patient, with patients with Crohn’s disease: a Pilot Study (ACROHEMEIN). J. Clin. Med. 9 (1) (2019) 41. doi:10.3390/jcm9010041. PubMed PMID: 31878146.

G. Riveau, D. Deplanque, F. Remou, A.M. Schacht, H. Vlodounogov, M. Capron, et al., Helminth and immunomodulatory rBST antigen in a randomized, double-blind, placebo-controlled trial of a candidate vaccine against intestinal schistosomiasis, PLoS Negl. Trop. Dis. 6 (7) (2012) e1704. Epub 2012/07/18. doi:10.1371/journal.pntd.0001704. PubMed PMID: 22802974; PubMed Central PMCID: PMCP3162203.

G. Riveau, A.M. Schacht, J.P. Dompmair, D. Deplanque, M. Seck, N. Waucquet, et al., Safety and efficacy of the rsh28GST intestinal schistosomiasis vaccine: a phase 3 randomized, controlled trial in Senegalese children, PLoS Negl. Trop. Dis. 12 (12) (2018) e0006806. Epub 2018/12/12. doi:10.1371/journal.pntd.0006806. PubMed PMID: 29077017; PubMed Central PMCID: PMCP3559493.

A. Viswanath, S.N.S. Yarrarapu, M. Williams, In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PubMed PMID: 3092492; PubMed Central PMCID: PMCP1799511.

M.F. Hawash, M. Betson, A.J. Al-Jubury, H. Kringel, S.M. Thamsborg, C.M.O. Kapel, et al., Helminth secretome: the role in host disease, Trends Parasitol. 31 (6) (2015) 259–265. Epub 2015/05/26. doi:10.1016/j.pt.2015.04.007. PubMed PMID: 25996410.

A. Looss, Zur Lebensgeschichte des Trichuris muris. Cent. Bayer. Akad. Wiss. München. 1906. 201. 488–491.
[63] D.E. Beasley, A.M. Koltz, J.E. Lambert, N. Fierer, R.R. Dunn, The evolution of stomach acidity and its relevance to the human microbiome, PLoS One 10 (7) (2015), https://doi.org/10.1371/journal.pone.0134116.e0134116.e. PubMed PMID: 26222383.

[64] S. Baliga, S. Muglikar, R. Kale, Salivary pH: a diagnostic biomarker, J. Indian Soc. Periodontol. 17 (4) (2013) 461–465, https://doi.org/10.4103/0972-124X.118317. PubMed PMID: 24174725.

[65] Aoyama K-i, Y. Okino, H. Yamazaki, R. Kojima, M. Uchibori, Y. Nakanishi, et al., Saliva pH affects the sweetness sense, Nutrition 35 (2017) 51–55, https://doi.org/10.1016/j.nut.2016.10.018.

[66] J.B. Dressman, R.R. Berardi, I.C. Dermentzoglou, T.L. Russell, S.P. Schmaltz, J. L. Barnett, et al., Upper gastrointestinal (GI) pH in young, healthy men and women, Pharm. Res. 7 (7) (1990) 756–761, https://doi.org/10.1023/A:1015827908389.

[67] E. Foltz, S. Azad, M.L. Everett, Z.E. Holzknecht, N.L. Sanders, J.W. Thompson, et al., An assessment of human gastric fluid composition as a function of PPI usage, Phys. Rep. 3 (1) (2015), https://doi.org/10.14014/phy2.12269. Epub 2015/01/30. PubMed PMID: 25626870; PubMed Central PMCID: PMCPMC4387745.

[68] J. Fallingborg, Intraluminal pH of the human gastrointestinal tract, Dan. Med. Bull. 46 (3) (1999) 183–196. Epub 1999/07/28. PubMed PMID: 10421978.